NCT00722098终止2 期
Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Induction of melanoma-specific CD8+T Cell Immunity.
研究概览
简要总结
The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
详细描述
Vaccination of patients with metastatic melanoma using ex vivo generated dendritic cells (DCs) loaded with tumor-associated antigen(s) have been shown to induce tumor-specific immunity against melanoma antigens measured by in vitro assays and, in some cases, tumor regression. At the present time, the numbers of recorded patients with metastatic melanoma who have been treated with DC vaccinations are too small to predict with certainty the future of overall therapeutic value of DC vaccinations in the management of patients with metastatic melanoma. The purpose of this study is to gather data on feasibility and efficacy of novel combination therapy of CPA and a DC vaccine outlined in this protocol to treat metastatic melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven metastatic melanoma, Stages M1a, M1b, M1c
- •HLA-A*0201 phenotype
- •Age: 21-75 years
- •ECOG performance status 0-1
- •Measurable metastatic melanoma lesions by physical examination or radiographs or scans.
- •Adequate marrow function:
- •White count ≥ 4,000/microliter: Subjects who have recently completed chemotherapy will be allowed study entry with White count ≥ 3,500/microliter
- •Hemoglobin ≥ 10.0 gm: Subjects who have recently completed chemotherapy will be allowed study entry with Hemoglobin ≥ 9.0 gm.
- •Platelets ≥ 100,000/microliter
- •Adequate hepatic function:
- •Bilirubin ≤ 1.5/mg/dL
- •Alkaline phosphatase ≤ 5 times the upper limit of normal
- •SGOT ≤ 5 times the upper limit of normal
- •SGPT ≤ 5 times the upper limit of normal
- •Adequate renal function:
- •Serum creatinine ≤ 1.5/mg/dL
- •No active CNS metastatic disease at screening.
- •Patients with a history of CNS melanoma lesions must have had lesions resected by surgery and/or gamma knife irradiation at least 3 months prior to study entry.
- •The total number of CNS lesions at diagnosis should not have exceeded
- •Written informed consent
排除标准
- •Patients who have received > 8 cycles of cytotoxic chemotherapy or metastatic melanoma
- •Patients who have received any chemotherapy < 4 weeks before the beginning of the trial
- •Patients who have received interferon alpha (IFNα-2b) or sargramostim (GM-CSF) < 4 weeks before the beginning of the trial
- •Patients who have received high-dose interleukin-2 (IL-2) < 4 weeks before the beginning of the trial
- •Patients that have been diagnosed with more than 3 CNS melanoma lesions.
- •Patients that have been diagnosed with more than 5 hepatic metastases or any hepatic metastasis > 5 cm.
- •Baseline serum LDH > 1.1 times the upper limit of normal
- •Patients who are HIV+ (HIV patients are often profoundly immunodeficient because of the viral infection and this additional parameter will interfere with the evaluation of DC induced immune responses in melanoma patients. Furthermore, the safety of collecting DCs, loading them with antigen and re-infusing these cells to HIV+ patients has not yet been determined.)
- •Pregnancy (Pregnancy is associated with considerable immunosuppression 70 and this additional parameter will interfere with the evaluation of DC induced immune responses in melanoma patients. In addition, the safety and tolerability of cell body-loaded DC given subcutaneously is entirely unknown.)
- •Patients who have received corticosteroids or other immunosuppressive agents < 4 weeks before beginning the trial
- •Patients with active asthma and/or on treatment for asthma
- •Patients with angina pectoris
- •Patients with congestive heart failure
- •Patients with a history of autoimmune disease including lupus erythematosus, rheumatoid arthritis or thyroiditis
- •Patients with active infections including viral hepatitis
- •Patients with a history of neoplastic disease other than melanoma < 5 years prior to entry on the trial except for patients with carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin. Patients who have any of these two types of cancer and melanoma can be included.
结局指标
主要结局
Induction of melanoma-specific CD8+T Cell Immunity.
时间窗: 2 years
次要结局
- Rate of objective clinical responses.(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma PatientsMelanomaNCT01308294Centre Hospitalier Universitaire Vaudois16
已完成
1 期
Immunotherapy of Melanoma PatientsMelanomaNCT00112216Centre Hospitalier Universitaire Vaudois9
尚未招募
2 期
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in TreatingRenal NeoplasmaNCT02487550The First People's Hospital of Changzhou1,200
终止
1 期
Dendritic Cell Based Therapy of Metastatic Breast CancerMetastatic Breast CancerNCT00197925Herlev Hospital40
已完成
1 期
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance MelanomaMetastatic MelanomaNCT00626860Beth Israel Deaconess Medical Center20